Join us as we explore Theriva Biologics' innovative approach to oncolytic virus therapies, aimed at improving survival rates for difficult-to-treat cancers like brain tumors and pancreatic cancers. Learn about their leading candidate, VCN-01, and the promising results seen in clinical trials for various types of cancer. Discover how Theriva is pushing the boundaries with next-generation viruses like VCN-11 with Albumin Shield technology, paving the way for future advancements in cancer treatment.
